Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the chemical formula C21H25ClFN3O3S and a molecular weight of approximately 454 Da[1][5][7]. It features a polycyclic aromatic structure containing both benzene and 1,2,4‑oxadiazole rings. The compound was developed as part of research into dipeptidyl peptidase IV (DPP‑IV or DPP‑4) inhibitors—a class of drugs that modulate glucose metabolism by inhibiting the enzyme DPP‑IV. This mechanism is relevant for potential antidiabetic therapies. The compound has been described in medicinal chemistry literature as a potent fluoroolefin-derived DPP‑IV inhibitor but has not advanced beyond preclinical or early experimental stages[8]. There are no approved indications or clinical trials reported for this molecule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (2S,3S)-3-{3-[2-chloro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-cyclopentylidene-4-cyclopropyl-1-fluorobutan-2-amine.